Your institution may have access to this item. Find your institution then sign in to continue.
Title
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Authors
Algazi, A P; Weber, J S; Andrews, S C; Urbas, P; Munster, P N; DeConti, R C; Hwang, J; Sondak, V K; Messina, J L; McCalmont, T; Daud, A I
Abstract
Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.
Publication
British journal of cancer, 2012, Vol 106, Issue 1, p85